Screener / SEC EDGAR /CIK 0002046386 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

Medline Inc. MDLN

Compare with peers Embed
FY2025 at a glance

Sales up 11.5%

XBRL, from each 10-K
RevenueStatements
$28.4B
FY2023FY2025
Net incomeStatements
$1.2B from $1.2B in FY2025
FY2023FY2025
Free cash flowStatements
$1.3B
FY2023FY2025
EPS (diluted)Statements
$-0.01
Operating marginStatements
7.8%
FY2023FY2025
Total debtStatements
$12.6B
FY2023FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (39)
EPS (ttm)
-0.01
Sales (ttm)
30.7B
Net income (ttm)
1.2B
Sales growth
+11.5%
EPS growth
-
Sales Q/Q
+10.4%
Free cash flow
1.9B
Gross margin
25.7%
Oper. margin
5.7%
Net margin
4.1%
FCF margin
6.2%
ROE
9.8%
ROA
2.9%
R&D / sales
0.3%
Dividend
-
Debt/Eq
1.07
Curr. ratio
4.04
Cash
2.3B
Op. cash flow (ttm)
2.4B
EBITDA
3.2B
EBITDA margin
11.3%
Net debt
10.3B
Quick ratio
2.52
Interest cover
2.34
ROIC
8.4%
FCF after stock pay
1.2B
Debt / FCF (years)
9.70
Goodwill / assets
21.0%
Tax rate
7.3%
Stock pay / sales
0.3%
Shares out.
1.3B
Book / share
8.96
Cash / share
1.76
Sales / share
23.31
Asset turnover
0.76
Inventory turns
4.39
Days sales out.
45
Employees
45,000
Sales / employee
682K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2023 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 28.4B +10.6% a year Net income 1.2B +122.6% a year
FY2023 revenue 23.2B · Revenues, 0002046386-26-000009 FY2023 net income 234.0M · ProfitLoss, 0002046386-26-000009 23.2B FY2023 FY2024 revenue 25.5B · Revenues, 0002046386-26-000009 FY2024 net income 1.2B · ProfitLoss, 0002046386-26-000009 25.5B FY2024 FY2025 revenue 28.4B · Revenues, 0002046386-26-000009 FY2025 net income 1.2B · NetIncomeLoss, 0002046386-26-000009 28.4B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2023 to FY2025 (2 years).

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $10.7B
  • − All liabilities $19.2B
  • = Net current asset value -$8.5B
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $10.7B
  • − Goodwill $8.1B
  • − Other intangible assets $13.9B
  • = Tangible book value -$11.2B

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

MDLN against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+11.5%73rd of 155 · median +10.5%
Net margin
-4.1%15.3%
4.1%85th of 154 · median 6.8%
Return on equity
-5.2%18.5%
9.8%69th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
6.2%90th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
1.0777th of 108 · median 0.69
MDLN and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
MDLN Medline Inc.$30.7B +11.5%25.7%4.1%9.8%6.2%1.07
MDT Medtronic$37.5B +8.4%65.0%13.9%10.4%16.3%0.56
GILD Gilead Sciences$31.0B +2.4%79.9%-12.5%-29.6%44.5%2.01
SYK Stryker Corporation$26.3B +11.2%65.3%13.8%15.4%17.4%0.61
DHR Danaher Corporation$25.6B +2.9%58.6%16.9%8.1%22.4%0.53
BDX Becton Dickinson$22.5B +8.2%46.9%4.2%3.9%14.2%0.69
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by segment

From $23.2B of sales to $234.0M of profit FY2023

  • Supply Chain Solutions $11.6B
  • Medline Brand $11.6B
Revenue to Gross profit: $5.9BRevenue to Cost of revenue: $17.3BGross profit to Operating profit: $1.2BGross profit to Operating expenses: $4.6BOperating profit to Net profit: $234.0MOperating profit to Tax & other: $1.0BOperating expenses to R&D: $60.0MOperating expenses to Sales, admin & other: $4.6B Revenue: $23.2B REVENUE $23.2B Gross profit: $5.9B · 25% margin GROSS PROFIT $5.9B 25% margin Cost of revenue: $17.3B · 75% of revenue COST OF REVENUE $17.3B 75% of revenue Operating profit: $1.2B · 5% margin OPERATING PROFIT $1.2B 5% margin Operating expenses: $4.6B · 20% of revenue OPERATING EXPENSES $4.6B 20% of revenue Net profit: $234.0M · 1% margin NET PROFIT $234.0M 1% margin Tax & other: $1.0B · 4% of revenue TAX & OTHER $1.0B 4% of revenue R&D: $60.0M · 0% of revenue R&D $60.0M 0% of revenue Sales, admin & other: $4.6B · 20% of revenue SALES, ADMIN & OTHER $4.6B 20% of revenue

From $25.5B of sales to $1.2B of profit FY2024

  • Supply Chain Solutions $13.0B
  • Medline Brand $12.5B
Revenue to Gross profit: $7.0BRevenue to Cost of revenue: $18.5BGross profit to Operating profit: $2.1BGross profit to Operating expenses: $4.8BOperating profit to Net profit: $1.2BOperating profit to Tax & other: $983.0MOperating expenses to R&D: $67.0MOperating expenses to Sales, admin & other: $4.8B Revenue: $25.5B REVENUE $25.5B +10% Y/Y Gross profit: $7.0B · 27% margin GROSS PROFIT $7.0B 27% margin · +19% Y/Y Cost of revenue: $18.5B · 73% of revenue COST OF REVENUE $18.5B 73% of revenue Operating profit: $2.1B · 8% margin OPERATING PROFIT $2.1B 8% margin · +72% Y/Y Operating expenses: $4.8B · 19% of revenue OPERATING EXPENSES $4.8B 19% of revenue Net profit: $1.2B · 5% margin NET PROFIT $1.2B 5% margin · +397% Y/Y Tax & other: $983.0M · 4% of revenue TAX & OTHER $983.0M 4% of revenue R&D: $67.0M · 0% of revenue R&D $67.0M 0% of revenue Sales, admin & other: $4.8B · 19% of revenue SALES, ADMIN & OTHER $4.8B 19% of revenue

From $28.4B of sales to $1.2B of profit FY2025

  • Supply Chain Solutions $14.7B
  • Medline Brand $13.7B
Revenue to Gross profit: $7.5BRevenue to Cost of revenue: $20.9BGross profit to Operating profit: $2.2BGross profit to Operating expenses: $5.3BOperating profit to Net profit: $1.2BOperating profit to Tax & other: $1.1BOperating expenses to R&D: $80.0MOperating expenses to Sales, admin & other: $5.2B Revenue: $28.4B REVENUE $28.4B +11% Y/Y Gross profit: $7.5B · 26% margin GROSS PROFIT $7.5B 26% margin · +8% Y/Y Cost of revenue: $20.9B · 74% of revenue COST OF REVENUE $20.9B 74% of revenue Operating profit: $2.2B · 8% margin OPERATING PROFIT $2.2B 8% margin · +3% Y/Y Operating expenses: $5.3B · 19% of revenue OPERATING EXPENSES $5.3B 19% of revenue Net profit: $1.2B · 4% margin NET PROFIT $1.2B 4% margin · +0% Y/Y Tax & other: $1.1B · 4% of revenue TAX & OTHER $1.1B 4% of revenue R&D: $80.0M · 0% of revenue R&D $80.0M 0% of revenue Sales, admin & other: $5.2B · 18% of revenue SALES, ADMIN & OTHER $5.2B 18% of revenue

Where each $100 of sales went

FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax & other
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 · 10-K XBRL, year-end balances

Return on equity 10.8% net income ÷ equity
Net margin 4.1% profit per $ of sales: 1.2B ÷ 28.4B
Asset turnover 0.74× sales per $ of assets: 28.4B ÷ 38.5B
Leverage 3.58× assets per $ of equity: 38.5B ÷ 10.7B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    4.1% vs 6.8%
  • Gross margin up over 2 years
    25.3% → 26.4%
  • Return on equity below 15%
    9.8%
  • A profit in every one of 3 years
Net margin, FY2023 to FY2025: 1.0% to 4.1%

Balance sheet

  • Interest covered less than 5 times
    Operating income is 2.3× interest expense
  • Debt larger than equity
    Debt / equity 1.07 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 4.04
  • Net debt over 3 years of free cash flow
    $10.3B net debt, 5.4 years

Cash and shareholders

  • Free cash flow positive in every one of 3 years
    $1.3B last year
  • Cash from operations above net income
    $1.7B vs $1.2B
Free cash flow, FY2023 to FY2025: 1.4B to 1.3B

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$8.1B of principal due, schedule of Sep 26, 2026

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

MDLN's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 4. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue28.4B
FY2023: 23.2BFY2024: 25.5BFY2025: -FY2025: 28.4B FY2023FY2024FY2025FY2025
Net income1.2B
FY2023: 234.0MFY2024: 1.2BFY2025: 1.2BFY2025: 1.2B FY2023FY2024FY2025FY2025
Free cash flow1.3B
FY2023: 1.4BFY2024: 1.4BFY2025: -FY2025: 1.3B FY2023FY2024FY2025FY2025
Free cash flow after stock pay1.2B
FY2023: 1.3BFY2024: 1.4BFY2025: -FY2025: 1.2B FY2023FY2024FY2025FY2025

Revenue by business segment

year to Dec 31, 2025
RevenueSharevs year before
Supply Chain Solutions 14.7B51.7% +13.2%
Medline Brand 13.7B48.3% +9.6%

10-K 0002046386-26-000009, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
United States 26.5B93.1% +11.5%
International 2.0B6.9% +11.0%

10-K 0002046386-26-000009, segment and revenue notes (XBRL).

Revenue by business segment, 3 years

from the segment notes of the last 1 10-Ks
FY2023FY2024FY2025
Supply Chain Solutions11.6B13.0B14.7B
Medline Brand11.6B12.5B13.7B
Sum of segments23.2B25.5B28.4B

Revenue and operating income by business segment, as each 10-K reports them in its segment note (XBRL). Each year comes from the newest 10-K that reports it, so a year the company later recast shows the recast number; click a number to open that 10-K. Rows without a number were not reported as a separate segment that year. "Corporate and other" and "All other" are the 10-K's own lines for what is outside the segments.

Income statement

From EDGAR
FY2023FY2024FY2025FY2025
Revenue23.2B25.5B-28.4B
Cost of revenue17.3B18.5B-20.9B
Gross profit5.9B7.0B-7.5B
R&D60.0M67.0M-80.0M
SG&A3.9B4.1B-4.5B
Operating income1.2B2.1B-2.2B
Interest expense1.2B1.1B-945.0M
Pretax income264.0M1.2B-1.2B
Income tax30.0M46.0M-91.0M
Net income234.0M1.2B1.2B1.2B
EPS (diluted)----0.01
Diluted shares---810.0M
Depreciation & amortization951.0M977.0M-1.0B
EBITDA2.2B3.1B-3.2B
Gross margin25.3%27.3%-26.4%
Operating margin5.4%8.4%-7.8%
Net margin1.0%4.6%-4.1%
Revenue growth-+9.8%-+11.5%

Balance sheet

From EDGAR
FY2023FY2024FY2025FY2025
Cash1.6B199.0M-1.9B
Short-term investments---0
Receivables-3.2B-3.5B
Inventory-4.5B-4.8B
Current assets-8.3B-10.7B
Property & equipment-4.6B-4.8B
Goodwill7.5B8.1B-8.1B
Other intangible assets-14.6B-13.9B
Total assets-36.0B-38.5B
Accounts payable-869.0M-961.0M
Current liabilities-2.4B-2.5B
Total debt-16.5B-12.6B
Total liabilities-19.5B-19.2B
Shareholders' equity---10.7B
Retained earnings----7.0M

Cash flow

From EDGAR
FY2023FY2024FY2025FY2025
Operating cash flow1.7B1.8B-1.7B
Capital spending275.0M354.0M-447.0M
Free cash flow1.4B1.4B-1.3B
Stock-based pay (added back)78.0M61.0M-76.0M
Free cash flow after stock pay1.3B1.4B-1.2B
Buybacks020.0M-33.0M
Acquisitions16.0M1.1B--6.0M
Investing cash flow-312.0M-1.5B--474.0M
Financing cash flow-191.0M-1.6B-399.0M

Stock-based pay and leases

From EDGAR
FY2023FY2024FY2025FY2025
Stock-based pay (expense)78.0M61.0M-76.0M
Stock-based pay / revenue0.3%0.2%-0.3%
Operating lease cost67.0M90.0M-106.0M
Operating lease cash paid56.0M84.0M-109.0M
Right-of-use assets-384.0M-432.0M
Operating lease liabilities-405.0M-452.0M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MDLN/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.